- FoI Number
- 2023-601
- Subject
- Immunomodulatory Medications
- Date Received
- 08/01/2024
- Request and Response
-
- How many patients has your trust/health board treated in the past 6 months (for any disease) with the following drugs:
- Aubagio (teriflunomide) 0
- Avonex (interferon beta-1a) 0
- Betaferon (interferon beta-1b) 0
- Brabio (glatiramer acetate) <5
- Copaxone (glatiramer acetate) <5
- Extavia (beta interferon-1b) <5
- Gilenya (fingolimod) <5
- Lemtrada (alemtuzumab) 0
- Kesimpta (ofatumumab) 0
- Mavenclad (cladribine) 0
- Mayzent (siponimod) 0
- Ocrevus (ocrelizumab) <5
- Plegridy (peginterferon beta-1a) 0
- Ponvory (ponesimod) 0
- Rebif (beta interferon-1a) 0
- Tecfidera (dimethyl fumarate) 19
- Tysabri (natalizumab) 0
- Tysabri (natalizumab) pre-filled syringes ONLY 0
- Vumerity (diroximel fumarate) 0
- Zeposia (ozanimod) 0
Where we have given <5 answers, this is because NHS Shetland considers that providing more specific information carries a high risk of identifying individuals. As such and in accordance with FOISA s 16(1), NHS Shetland confirms that it holds the information requested but that it is exempt from disclosure under FOISA s 38(1)(b) as read with s 38 (2A) as the information constitutes personal data and disclosure would breach the confidentiality of the data subjects.
